The key for the Early Detection Research Network (EDRN)'s success lies in good communication among scientists in multiple disciplines;efficient evaluation and prioritization of promising biomarkers;and rigorous validation studies to demonstrate their clinical utility. The overall aims of the proposed renewal of the Data Management and Coordinating Center (DMCC) are to (i) provide coordination of EDRN in order to enhance communication and collaboration among EDRN investigators and with general scientific communities;(ii) coordinate EDRN validation studies;(iii) conduct theoretical and applied statistical research relevant to cancer risk prediction, early detection, and prognosis;and (iv) disseminate cancer biomarker information to broader scientific communities and public. Under the direction of the EDRN Steering Committee, the DMCC Will 1) perform network coordination and promote collaborations among scientific investigators by providing support for EDRN meetings and workshops, developing and maintaining EDRN secure websites and istservs, producing and maintaining all EDRN documents, and maintaining the online review system for applications submitted to the EDRN;2) support EDRN validation studies by developing and maintaining validation study data management systems;working with EDRN investigator on study design, protocol development, data forms, and study manuals;coordinating and monitoring studies;tracking specimens;and performing QA/QC and study evaluation;3) develop statistical methodologies and computational tools needed by EDRN for biomarker discovery and validation, with the emphasis on validation;and 4) work with NCI and JPL to provide informatic resources for the EDRN Secure Web site for data security, data warehouse, and data sharing, and a Public Website for dissemination.

Public Health Relevance

The proposed study is highly relevant to public health because early detection has great potential to reduce cancer burden. Rigorous evaluation of biomarker tests for their clinical utilities is imperative for public health.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-4 (M1))
Program Officer
Wagner, Paul D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Pepe, Margaret S; Janes, Holly; Li, Christopher I (2014) Net risk reclassification p values: valid or misleading? J Natl Cancer Inst 106:dju041
Danaher, Patrick; Wang, Pei; Witten, Daniela M (2014) The joint graphical lasso for inverse covariance estimation across multiple classes. J R Stat Soc Series B Stat Methodol 76:373-397
Feng, Sherry; Weaver, Donald L; Carney, Patricia A et al. (2014) A framework for evaluating diagnostic discordance in pathology discovered during research studies. Arch Pathol Lab Med 138:955-61
Huang, Ying; Pepe, Margaret S; Feng, Ziding (2013) LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS. Ann Appl Stat 7:
Pepe, Margaret Sullivan; Fan, Jing; Seymour, Christopher W (2013) Estimating the receiver operating characteristic curve in studies that match controls to cases on covariates. Acad Radiol 20:863-73
Feng, Ziding; Kagan, Jacob; Pepe, Margaret et al. (2013) The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clin Chem 59:68-74
Huang, Ying; Gilbert, Peter B; Janes, Holly (2012) Assessing treatment-selection markers using a potential outcomes framework. Biometrics 68:687-96
Janssens, A Cecile J W; Ioannidis, John P A; Bedrosian, Sara et al. (2011) Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. Eur J Epidemiol 26:313-37
Pepe, Margaret S; Janes, Holly (2011) Commentary: Reporting standards are needed for evaluations of risk reclassification. Int J Epidemiol 40:1106-8
Clark, Jarrod P; Munson, Kristofer W; Gu, Jessie W et al. (2008) Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem 54:2007-17